Skip to main content

Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study



Frequent supraventricular arrhythmia is associated with increased incidence of atrial fibrillation. However, it is unknown whether the prognostic significance of supraventricular arrhythmia is modified by plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) or troponin T (TnT). This study examined the interrelationships between NT-proBNP, TnT levels and frequent supraventricular arrhythmia, and whether these biomarkers and a measure of frequent supraventricular arrhythmia could improve risk assessment for incidence of AF.


Supraventricular extrasystoles (SVEs) and supraventricular tachycardias were assessed from 24-h electrocardiograph recordings in 373 individuals initially without AF. Elevated NT-pro-BNP, TnT and SVEs was defined as a measurement in the top quartile of the study population distribution. Incident cases of AF were retrieved by linkage with the Swedish National Patient Register.


During a mean follow-up of 15.4 years, 88 subjects had a diagnosis of AF. After multivariable adjustment, individuals with both elevated NT-proBNP and frequent SVEs had a significantly increased incidence of AF, compared to subjects without elevated NT-proBNP or frequent SVEs (hazard ratio (HR) 4.61, 95% confidence interval (CI) 2.45–8.69), and compared to individuals with either elevated NT-proBNP or frequent SVEs (both P < 0.05). HRs for frequent SVEs alone or elevated NT-proBNP alone were 2.32 (95% CI 1.33–4.06) and 1.52 (95% CI 0.76–3.05), respectively. The addition of NT-pro-BNP and SVEs to a validated risk prediction score for AF, CHARGE-AF, resulted in improved prediction (Harrell’s C 0.751 (95% CI 0.702–0.799) vs 0.720 (95% CI 0.669–0.771), P = 0.015).


Subjects with both elevated NT-proBNP and frequent SVEs have substantially increased risk of AF, and the use of these variables could improve long-term prediction of incident AF.

Peer Review reports


Atrial fibrillation (AF) is the most common sustained arrhythmia, especially among the elderly, and is associated with increased mortality and morbidity [1,2,3]. Improved risk assessment and early identification of individuals with high risk of AF could improve stroke prevention and lead to important public health benefits. Even though there are currently no validated prevention programs for AF, recent research indicates that early stages of the disease could be reversible [4, 5]. Furthermore, since AF can be asymptomatic, stroke events associated with AF may occur before AF is diagnosed. If individuals with high AF risk could be identified, this could enable repeated or prolonged electrocardiogram (ECG) monitoring, and early anticoagulation in order to prevent stroke.

Although the pathophysiology of AF is complex, considerable advances have been made in understanding the underlying pathophysiological mechanisms. There is convincing evidence that atrial myopathy, a state of atrial structural and electrical remodeling, precedes the development of AF [6, 7]. Structural remodeling includes atrial dilation and myocardial damage. This may result in elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T (TnT) [8, 9], both of which have been linked to a greater risk of AF [10, 11]. Electrical remodeling, on the other hand, can be measured by increased frequency of supraventricular extrasystoles (SVEs) and supraventricular tachycardias (SVTs), which are also highly related to AF risk [12,13,14,15,16]. It is plausible, therefore, that subjects with both elevated NT-pro-BNP or TnT and frequent supraventricular extrasystoles could have substantially increased risk of AF.

The CHARGE-AF score is a well validated risk score for prediction of AF, and a simplified form of the score can be calculated from clinically available parameters [17, 18]. The aim of this study was to examine whether the predictive value for incident AF is improved by combining SVEs and NT-proBNP or TnT levels, and if these risk factors add predictive information on top of the validated CHARGE-AF risk score for AF.


Study population

The study population was derived from the population-based, prospective Malmö Diet and Cancer Study cohort, which has been described elsewhere [16], and which consists of 30,446 individuals (age range 44–73 years, 39.8% men) recruited during the period of 1991–1996. A subsample consisting of 6103 individuals were randomly invited to receive additional screening in a cardiovascular sub-study. In 1998–2000, a re-examination was performed for 909 individuals from the cardiovascular sub-study. These individuals were randomly invited after stratification for degree of insulin resistance, as measured by the homeostasis model assessment for insulin resistance (HOMA-IR, calculated as fasting insulin (mIU/l) fasting blood glucose (mmol/l)/22.5)). High HOMA-IR was slightly oversampled (15% from each of quartiles 1 and 2, 30% from quartile 3, and 40% from quartile 4). Of the 909 individuals, a random subsample of 388 individuals underwent 24hECG screening (age range 53–74, 45.6% men). The study conforms to the declaration of Helsinki. Subjects with inadequate 24hECG recordings (n = 5), a diagnosis of AF (n = 6), missing NT-proBNP and TnT results (n = 4) were excluded; resulting in a final study population consisting of 373 subjects in total. Due to missing data for HOMA-IR score (n = 7), low density lipoprotein (LDL) (n = 1), and height and weight (n = 1), multivariable models included 364 subjects (Additional file 1: Supplementary Figure 1).

Data collection

Physical examination was performed for all subjects at baseline. Height and weight were measured standing in light indoor clothing, using a fixed stadiometer and a balance beam scale. Blood pressure was measured after 10 min supine rest, using a sphygmomanometer with a modifiable cuff. All patients completed an extensive self-administered questionnaire, from which current smoking status was retrieved. History of diabetes, coronary events, and heart failure were obtained through a combination of information from questionnaires and data from hospital registers. Blood samples were drawn after overnight fast and analyzed using standard laboratory procedures at the Malmö University Hospital. The samples were stored at − 70 °C. Plasma samples were analyzed by electrochemiluminescence using R-PLEX human NT-proBNP and R-PLEX human TnT (cardiac) assays (Meso Scale Discovery, Gaithersburg, MD) on a Sector S600 instrument at the Clinical Biomarkers Facility, SciLifeLab, Uppsala, Sweden. The NT-proBNP assay was run at a 1:10 dilution (average dynamic range 1.1 pg/ml–10,000 pg/ml) whereas Troponin T was run neat (average dynamic range 4.4 pg/ml to 500 pg/ml).

24-h ECG

All patients underwent a 24-h 3-lead (X, Y, Z coupling) Holter ECG recording, with 256-Hz sampling rate, for arrhythmia detection, which has been described before [16]. The equipment used was Life card CF digital Holter recorder with 12-bit resolution (Spacelabs Health care, Issaquah, WA). Findings were classified using the Pathfinder SL analysis tool (Spacelabs Healthcare). All ECG recordings were manually verified. Mean analysis time was 23.2 h, with a standard deviation (SD) of 1.2 h. SVEs was defined as a premature narrow complex beat preceded by a normal sinus beat. Three or more consecutive SVEs with a heart rate ≥ 100 beats per minute was defined as a SVT.

CHARGE-AF risk score

The CHARGE-AF risk score was calculated for each individual according to previously described specifications [18, 19]. Briefly, the score is calculated  as follows: 0.508 × age (5 years) + 0.248 × height (10 cm) + 0.115 × weight (15 kg) + 0.197 × systolic blood pressure (20 mm Hg) − 0.101 × diastolic blood pressure (10 mm Hg) + 0.359 × current smoker + 0.349 × antihypertensive medication + 0.237 × diabetes + 0.701 × congestive heart failure + 0.496 × myocardial infarction. In the present study, age, height, weight, systolic and diastolic blood pressure, current smoking status, antihypertensive medication, diabetes, history of heart failure, and history of coronary event (including coronary artery bypass grafting surgery and percutaneous coronary intervention) at baseline were used in the CHARGE-AF risk score calculations.

End-point ascertainment

Subjects were followed until first AF diagnosis (diagnosis codes 427D for the 9th revision of the International Classification of Diseases (ICD-9), and I48 for the 10th revision (ICD-10)), death, emigration, or end of the study (December 31, 2018), whichever came first. Atrial flutter was not distinguished from AF, due to the similarities between these diagnoses [20]. All endpoints were retrieved from the National Patient Register administered by the Swedish National Board of Health and Welfare, which covers all inpatient diagnoses since the year 1987 and all hospital outpatient diagnoses since the year 2000. A validation study of the AF cases in the Malmö Diet and Cancer study showed an accuracy of 95% [21]. The conventional duration of AF for diagnosis is 30 s in Sweden. The regional ethics review board in Lund has approved the study (LU 51/90).

Statistical methods

All analyses were performed using SPSS 25.0 and R 3.6.3. Negative binominal regression was used to estimate the relation between the numbers of SVEs per 24 h or SVTs per 24 h and per quartile increment in the NT-proBNP or TnT concentrations. Cox regression analyses were used to study the association between the combination of supraventricular arrhythmias and plasma biomarkers and incidence of AF. Elevated SVEs, SVTs, NT-proBNP, and TnT was defined as a measurement in the top quartile, corresponding to > 129.18 SVEs/24 h, 3.06 SVTs/24 h, 32.80 pg/ml NT-proBNP and > 1.38 pg/ml TnT. Elevated supraventricular activity (SVA) was defined as either the top quartile of SVEs or SVTs. Based on previous studies [16, 22], potential confounders which were related to both exposure and outcome were identified, and the following two pre-specified models were used. Model 1 adjusted for age and sex, and Model 2 additionally adjusted for current smoking, use of anti-hypertension medications, systolic blood pressure, LDL, natural log of HOMA-IR, height, and weight. A P-value below 0.05 denoted statistical significance.

The log-rank test was used to compare the cumulative incidence between combinations of NT-proBNP and SVEs, stratified by elevated CHARGE-AF-score (top tertile) or not (tertile 1,2). Performance of Cox regression models for AF was assessed using C-statistic. Differences in C-statistics between a model with CHARGE-AF alone and models with additional risk factors were compared by Student t test [23]. Furthermore, category free net reclassification improvement (NRI) was calculated for 15-year AF risk prediction to compare the predictive performance of the CHARGE-AF score model to models combining the CHARGE-AF score with measures of SVEs and biomarkers.


Baseline characteristics

The mean age at baseline was 64.0 ± 5.9 years. Of the 373 included individuals, 203 (54.4%) were women. At baseline 22.8% (n = 85) of study participants were smokers. Information of baseline characteristics is presented in Table 1.

Table 1 Baseline characteristics

Plasma biomarkers, supraventricular arrhythmias and incidence of AF

During a mean follow-up time of 15.4 years, 88 subjects were diagnosed with AF (cumulative incidence 23.6%). The number of SVEs and SVTs in 24 h were positively associated with quartiles of NT-proBNP and TnT concentrations (Fig. 1, Additional file 1: Supplementary Table 1). After multivariable adjustment NT-proBNP and TnT were related to the number of SVEs in 24 h (Odds ratio (OR)NT-proBNP = 1.64, 95% confidential interval (CI) 1.33–2.02; ORTnT = 1.33, 95% CI 1.10–1.60, both per quartile increase; Additional file 1: Supplementary Table 1). A similar association was observed for SVTs in 24 h: ORNT-proBNP = 1.60, 95% CI 1.27–2.02; ORTnT = 1.33, 95% CI 1.03–1.62 per quartile increase (Additional file 1: Supplementary Table 1).

Fig. 1

The relation between SVEs/SVTs in 24 h and quartiles of NT-proBNP/TnT. The numbers of SVEs and SVTs were transformed by lg(n + 1). a SVEs/24 h and NT-proBNP quartiles. b SVTs/24 h and NT-proBNP quartiles. c SVEs/24 h and TnT quartiles. d SVTs/24 h and TnT quartiles. The boxes illustrate median, 25th and 75th percentiles. Vertical lines include the 10th and 90th percentiles. Abbreviations NT-proBNP N terminal pro B type natriuretic peptide, SVEs supraventricular extrasystoles, SVTs supraventricular tachycardias, TnT troponin T

The association between the combinations of NT-proBNP and supraventricular arrhythmias with risk of AF is reported in Table 2. After multivariable adjustment individuals with both elevated NT-proBNP and elevated SVEs had the highest risk of incident AF, compared to subjects with normal values for both SVEs and NT-pro-BNP, and compared to subjects with either elevated SVEs or elevated NT-pro-BNP, for which groups an intermediate risk was observed. Similar results were found for combinations of NT-proBNP and SVTs, as well as NT-proBNP and SVA.

Table 2 Incidence of AF by occurrence of elevated NT-proBNP and frequent supraventricular arrhythmias

Results for the association of combinations of TnT and supraventricular arrhythmias with incident AF are presented in Table 3. The highest risk of AF was found among individuals with both elevated TnT and supraventricular arrhythmias compared to subjects without.

Table 3 Incidence of AF by occurrence of elevated TnT and frequent supraventricular arrhythmias

NT-proBNP, SVEs, and CHARGE-AF score

The relationship between NT-pro-BNP, SVEs and incidence of AF was also analyzed for elevated and normal levels of CHARGE-AF score. The combination of both elevated NT-pro-BNP and frequent SVEs was more common among subjects with an elevated CHARGE-AF score; 4.5% in the lower two tertiles compared to 19.0% in the top tertile (chi2 test value = 20.005, P < 0.001). Incidence of AF in individuals with high CHARGE-AF and both elevated NT-proBNP and elevated SVEs was 50.5 per 1000 as compared to 12.7 per 1000 for those with high CHARGE-AF score and normal SVEs and NT-proBNP (Fig. 2 and Additional file 1: Supplementary Figure 2).

Fig. 2

Incidence rates (95% confidence intervals) of AF in relation to a combination of elevated NT-proBNP and frequent SVEs stratified by elevated CHARGE-AF score. Frequent SVEs and elevated NT-proBNP were defined as the top quartile, corresponding to > 129.18 SVEs/24 h and 32.80 pg/ml NT-proBNP, respectively; elevated CHARGE-AF score was defined as top tertile. Abbreviations SVEs supraventricular extrasystoles, NT-proBNP N terminal pro B type natriuretic peptide

The CHARGE-AF risk score had good discrimination for incident AF (C-statistic 0.720, 95% CI 0.669–0.771; Table 4). The highest C-statistic was found for a model including CHARGE-AF risk score, elevated NT-proBNP, and frequent SVEs: 0.751 (95% CI 0.702–0.799); this was significantly higher than CHARGE-AF score alone (P = 0.015; Table 4). Similarly, the category-free NRI also showed significant improvements in prediction of AF when elevated NT-proBNP and frequent SVEs were simultaneously added on top of CHARGE-AF score (NRI = 0.300, 95% CI 0.166–0.452; Table 4).

Table 4 C-statistics and category free net reclassification improvement (NRI) of predictive models for incident AF


Findings from the current study suggest that subjects with both elevated NT-pro-BNP or TnT and frequent supraventricular ectopy have a markedly increased risk of incident AF. Among the 9.1% of the population with both elevated NT-pro-BNP and frequent SVEs, the absolute risk of incident AF was almost 5% per year, and by the end of follow-up more than half of the subjects in this group had been diagnosed with atrial fibrillation. This risk was similar regardless of CHARGE-AF score. Future studies of primary prevention of AF could focus on this population. Patients with AF are at risk of adverse outcomes, such as heart failure, thrombo-embolism and impaired cognitive function, and this results in substantial mortality and morbidity [24]. Earlier detection and prevention could therefore contribute to reduced AF-associated morbidity, mortality, and medical costs [25].

Both SVE and NT-pro-BNP are established predictors of AF. SVEs have been shown to be associated with incident AF in several cohorts sampled from American, European and Asian populations [14,15,16, 26]. SVT frequency is associated with incidence of AF independently of symptomatic cardiovascular disease in this cohort and the Copenhagen Holter Study [14, 16]. It is plausible that frequent supraventricular ectopic activity is a marker of existing electrical remodeling, a component of the emerging concept of atrial myopathy which is also characterized by structural remodeling [27]. Structural remodeling is characterized by atrial dilatation, as well as atrial strain [7], and these changes increase the secretion of NT-proBNP from atrium [6, 28,29,30,31]. Tissue fibrosis is another characteristic of structural remodeling; this observed in parallel with myocardial apoptosis or necrosis [32]. Troponin T, which is released during cardiomyocyte damage and could possibly reflect fibrosis, is also related to incident AF [11, 33, 34]. This study found a correlation between supraventricular arrhythmias and plasma biomarkers levels, and that the combination of NT-pro-BNP and frequent SVEs was more common among subjects with elevated CHARGE-score, which supports the idea that atrial myopathy is caused by established AF risk factors, and that intervention against modifiable risk factors may slow the progression from atrial myopathy to AF.

Several risk scores and equations have been developed for the prediction of AF [17]. Extensions of these models include information on blood biomarkers, echocardiographic and electrocardiographic measurements, or genetic variants, beyond the information provided by clinical variables [17]. The present study indicates that a model based on current knowledge of the pathophysiological mechanisms behind AF has the potential to further improve AF prediction, and identify subjects with a markedly increased AF risk. This group could potentially benefit from primary prevention and efforts for early detection of AF in order to prevent stroke.

Strengths and limitations

There are several strengths of present study. The mean age of the study population is relevant and corresponds to an age at which the incidence of AF is relatively high, but before the onset of the majority of AF cases [35]. The endpoint was retrieved from comprehensive patient registers that cover in- and outpatient hospital diagnoses in Sweden. Only two subjects were lost to follow-up due to emigration from Sweden. The registers do not cover AF patients that are treated in primary care only and it has been estimated that specificity and sensitivity is 93% and 80%, respectively, for an AF diagnosis in these registers [36]. Also, some incident cases with asymptomatic AF may have been missed. However, the high overall cumulative incidence of AF in this study (23.6%) is similar to the life-time risk of AF calculated in other-studies [1, 37], implying that few cases of incident AF have been missed.

The sample size of the population was limited, and in the case of weaker associations this would have resulted in a risk of type II error. The population was oversampled of individuals with insulin resistance and as such, this could be regarded as a population with an increased cardiometabolic risk. However, the results were adjusted for HOMA-IR and results were still statistically significant. There are some unmeasured factors which may lead to residual bias, such as other biomarkers. For example, von Willebrand factor is associated with incident AF [38]. In order to assess the risk of residual confounding, the E value was calculated [39] which estimates how strong any unmeasured confounder must be to remove the significance of the observed main results. The E value for the association between the combination of elevated NT-proBNP with frequent SVEs and AF incidence was 5.06 with the confidence limit of 3.11, suggesting that the observed association could be removed by an unmeasured confounder, which is related to both independent and dependent variable with a relative risk of 5.06, indicating a high robustness of current results.


We conclude that subjects with both frequent SVEs or SVTs and elevated NT-pro-BNP, are at markedly increased risk of AF. A combination of biomarkers and frequent SVEs or SVTs could improve long-term prediction of incident AF.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request, or upon request from the data access group of Malmö Diet and Cancer study.



Atrial fibrillation




N-terminal pro-brain natriuretic peptide


Troponin T


Supraventricular extrasystoles


Supraventricular tachycardias


Homeostasis model assessment for insulin resistance


Low density lipoprotein


Confidence interval


Odds ratio


Hazard ratio


Net reclassification improvement


  1. 1.

    Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–53.

    Article  Google Scholar 

  2. 2.

    Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229–34.

    CAS  Article  Google Scholar 

  3. 3.

    Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–52.

    CAS  Article  Google Scholar 

  4. 4.

    Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222–31.

    Article  Google Scholar 

  5. 5.

    Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20:1929–35.

    Article  Google Scholar 

  6. 6.

    Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol. 2008;51:1–11.

    Article  Google Scholar 

  7. 7.

    Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63:2335–45.

    Article  Google Scholar 

  8. 8.

    Tsai JP, Sung KT, Su CH, Lai YH, Kuo JY, Yun CH, et al. Diagnostic accuracy of left atrial remodelling and natriuretic peptide levels for preclinical heart failure. ESC Heart Fail. 2019;6:723–32.

    Article  Google Scholar 

  9. 9.

    Kawasaki T, Sakai C, Harimoto K, Yamano M, Miki S, Kamitani T. Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112:867–72.

    CAS  Article  Google Scholar 

  10. 10.

    Svennberg E, Lindahl B, Berglund L, Eggers KM, Venge P, Zethelius B, et al. NT-proBNP is a powerful predictor for incident atrial fibrillation—validation of a multimarker approach. Int J Cardiol. 2016;223:74–81.

    Article  Google Scholar 

  11. 11.

    Filion KB, Agarwal SK, Ballantyne CM, Eberg M, Hoogeveen RC, Huxley RR, et al. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015;169(31–8):e3.

    Google Scholar 

  12. 12.

    Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1:62–73.

    Article  Google Scholar 

  13. 13.

    Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011;124:2264–74.

    CAS  Article  Google Scholar 

  14. 14.

    Binici Z, Intzilakis T, Nielsen OW, Køber L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation. 2010;121:1904–11.

    CAS  Article  Google Scholar 

  15. 15.

    Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK, et al. Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. Ann Intern Med. 2013;159:721–8.

    Article  Google Scholar 

  16. 16.

    Johnson LS, Juhlin T, Juul-Möller S, Hedblad B, Nilsson PM, Engström G. A prospective study of supraventricular activity and incidence of atrial fibrillation. Heart Rhythm. 2015;12:1898–904.

    Article  Google Scholar 

  17. 17.

    Alonso A, Norby FL. Predicting atrial fibrillation and its complications. Circ J. 2016;80:1061–6.

    CAS  Article  Google Scholar 

  18. 18.

    Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2:e000102.

    Article  Google Scholar 

  19. 19.

    Christophersen IE, Yin X, Larson MG, Lubitz SA, Magnani JW, McManus DD, et al. A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. Am Heart J. 2016;178:45–54.

    Article  Google Scholar 

  20. 20.

    Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atrial flutter mechanisms and clinical implications. J Am Coll Cardiol. 2008;51:779–86.

    Article  Google Scholar 

  21. 21.

    Smith JG, Platonov PG, Hedblad B, Engström G, Melander O. Atrial fibrillation in the Malmö Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol. 2010;25:95–102.

    Article  Google Scholar 

  22. 22.

    Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable risk factors and atrial fibrillation. Circulation. 2017;136:583–96.

    Article  Google Scholar 

  23. 23.

    Schröder MS, Culhane AC, Quackenbush J, Haibe-Kains B. survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics. 2011;27:3206–8.

    Article  Google Scholar 

  24. 24.

    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.

    Article  Google Scholar 

  25. 25.

    Boriani G, Proietti M. Atrial fibrillation prevention: an appraisal of current evidence. Heart. 2018;104:882–7.

    Article  Google Scholar 

  26. 26.

    Chong BH, Pong V, Lam KF, Liu S, Zuo ML, Lau YF, et al. Frequent premature atrial complexes predict new occurrence of atrial fibrillation and adverse cardiovascular events. Europace. 2012;14:942–7.

    Article  Google Scholar 

  27. 27.

    Goldberger JJ, Arora R, Green D, Greenland P, Lee DC, Lloyd-Jones DM, et al. Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate. Circulation. 2015;132:278–91.

    Article  Google Scholar 

  28. 28.

    Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006;27:1648–50.

    CAS  Article  Google Scholar 

  29. 29.

    Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120:1768–74.

    CAS  Article  Google Scholar 

  30. 30.

    Patton KK, Heckbert SR, Alonso A, Bahrami H, Lima JA, Burke G, et al. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart. 2013;99:1832–6.

    CAS  Article  Google Scholar 

  31. 31.

    Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;56:1712–9.

    Article  Google Scholar 

  32. 32.

    Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802–9.

    CAS  Article  Google Scholar 

  33. 33.

    Eggers KM, Al-Shakarchi J, Berglund L, Lindahl B, Siegbahn A, Wallentin L, et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. Am Heart J. 2013;166:541–8.

    CAS  Article  Google Scholar 

  34. 34.

    Anegawa T, Kai H, Adachi H, Hirai Y, Enomoto M, Fukami A, et al. High-sensitive troponin T is associated with atrial fibrillation in a general population. Int J Cardiol. 2012;156:98–100.

    Article  Google Scholar 

  35. 35.

    Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274:461–8.

    CAS  Article  Google Scholar 

  36. 36.

    Baturova MA, Lindgren A, Carlson J, Shubik YV, Bertil Olsson S, Platonov PG. Atrial fibrillation in patients with ischaemic stroke in the Swedish national patient registers: how much do we miss? Europace. 2014;16:1714–9.

    Article  Google Scholar 

  37. 37.

    Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042–6.

    Article  Google Scholar 

  38. 38.

    Gragnano F, Golia E, Natale F, Bianchi R, Pariggiano I, Crisci M, et al. Von Willebrand factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target. Curr Vasc Pharmacol. 2017;15:404–15.

    CAS  Article  Google Scholar 

  39. 39.

    VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268–74.

    Article  Google Scholar 

Download references


The authors wish to thank all the participants and all medical and nursing staff for making this study possible. The SciLifeLab laboratory, Uppsala, Sweden, is acknowledged for assistance in biomarker analysis.


Open access funding provided by Lund University. Jun Xiao is supported by the China Scholarship Council (Grant No. 201908350096). Dr Johnson is supported by governmental funding within the Swedish National Health Services, the Swedish Society of Medicine (Grant No. SLS-888281), the Swedish Society of Cardiology, the Swedish Heart and Lung Association (Grant No. FA 2018:50) and the Bergqvist Foundation (Grant No. 139645). Dr Johnson and Dr Engström are supported by the Swedish Heart and Lung Foundation (Grant Nos. 20180211, 20190354, 20190224 and 20190294), Sparbanksstiftelsen Färs & Frosta and Swedish Research Council (2019–01236).

Author information




GE and LJ designed the study; GE and LJ acquired the data; JX, GE and LJ performed the statistical analysis and interpreted the results; JX drafted the first version of the manuscript; AP, GE and LJ read and critically reviewed the final version of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Jun Xiao or Linda S. B. Johnson.

Ethics declarations

Ethics approval and consent to participate

All participants provided informed consent and the studies were approved by The Ethics Committee of Lund University. The study conforms to the declaration of Helsinki.

Consent for publication

Not applicable.

Clinical relevance and future perspective

Those with both frequent supraventricular arrhythmia and elevated NT-proBNP have a high risk of future atrial fibrillation. This group could potentially benefit from primary prevention and efforts for early detection of AF.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplementary Figure 1

. Individuals included in this research. Supplementary Figure 2. Incidence of atrial fibrillation in relation to a combination of elevated NT-proBNP and frequent SVEs. Supplementary Table 1. Effect estimates of the association between number of SVEs/SVTs and NT-proBNP/TnT.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xiao, J., Persson, A.P., Engström, G. et al. Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study. BMC Cardiovasc Disord 21, 134 (2021).

Download citation


  • Atrial fibrillation
  • Supraventricular extrasystole
  • Premature atrial contractions
  • Supraventricular tachycardia
  • NT-proBNP
  • Troponin T